Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2018

View Archived Issues

Sleep is depression's opposite

Novel CRISPR/Cas-mediated rat model of idiosyncratic drug-induced liver injury

First-in-human data presented for AB-023

Aspirin increases lysosomal biogenesis via PPARalpha and decreases amyloid plaque pathology in mice

Motile sperm domain-containing protein 2 promotes breast cancer cell migration and metastasis

Estrogen receptor alpha activation depends on fibronectin-beta1-integrin pathway in breast cancer

Bench and bedside: Phosphatase inhibition sheds ugly duckling status with new platform technology

Beta Cat studies BC-2059 for unresectable desmoid tumors in phase I

Primary endpoints met in phase IIb study of PRX for presbyopia

Phase III study of RHB-104 in Crohn's disease meets primary endpoint

Regenera initiates phase II study of RPh-201 in NAION

Dong-A conducts phase II study with DA-8010 in overactive bladder

First-in-human study investigates CALR exon 9 mutant peptide vaccine in CALR-mutant MPNs

Janssen studies PRMT5 inhibitor JNJ-64619178 in advanced cancers

FDA approves Azedra for pheochromocytoma or paraganglioma

Arcus cleared to begin phase I trial of anti-TIGIT antibody AB-154

Stop-gain variant in GMIP gene tied to Alzheimer's disease pathogenesis

Contactin-2 levels are altered in mild cognitive impairment

ASTRAL-1 study of guadecitabine in AML does not meet coprimary endpoints

Immutep to begin phase II study of eftilagimod alfa with pembrolizumab

Regeneus reports promising first-in-human data for autologous tumor vaccine RGSH-4-K

Phase II study of laquinimod in Huntington's disease does not meet primary endpoint

European Commission approves Aimovig to prevent migraines

HSP27 found as a potential therapeutic target for treating VCID